$4.2 Billion is the total value of Rock Springs Capital Management LP's 123 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 23.8% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
PEN | Sell | PENUMBRA INC | $125,925,960 | +4.2% | 366,000 | -15.6% | 3.00% | +4.0% |
UNH | Sell | UNITEDHEALTH GROUP INC | $110,547,200 | -13.4% | 230,000 | -14.8% | 2.63% | -13.6% |
IDXX | Sell | IDEXX LABS INC | $97,683,735 | -5.9% | 194,500 | -6.3% | 2.32% | -6.1% |
ALGN | Sell | ALIGN TECHNOLOGY INC | $76,739,880 | -7.2% | 217,000 | -12.3% | 1.83% | -7.4% |
HZNP | Sell | HORIZON THERAPEUTICS PUB L | $50,910,750 | -37.0% | 495,000 | -33.1% | 1.21% | -37.2% |
SRPT | Sell | SAREPTA THERAPEUTICS INC | $48,671,000 | -20.2% | 425,000 | -4.0% | 1.16% | -20.4% |
MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $46,019,358 | -45.4% | 199,218 | -42.8% | 1.10% | -45.6% |
BMEA | Sell | BIOMEA FUSION INC | $18,369,911 | -54.3% | 836,898 | -35.5% | 0.44% | -54.5% |
KDNY | Sell | CHINOOK THERAPEUTICS INC | $15,225,078 | +29.6% | 396,280 | -21.9% | 0.36% | +29.3% |
MRSN | Sell | MERSANA THERAPEUTICS INC | $11,196,308 | -33.6% | 3,403,133 | -17.1% | 0.27% | -33.8% |
Sell | BIOHAVEN LTD | $9,606,846 | +2.6% | 401,624 | -41.4% | 0.23% | +2.7% | |
ANAB | Sell | ANAPTYSBIO INC | $6,948,897 | -44.6% | 341,637 | -40.7% | 0.16% | -44.8% |
NVTA | Sell | INVITAE CORP | $1,865,059 | -57.4% | 1,650,495 | -49.1% | 0.04% | -57.7% |
GMDA | Sell | GAMIDA CELL LTD | $1,379,994 | -27.3% | 715,023 | -69.5% | 0.03% | -26.7% |
NKTX | Sell | NKARTA INC | $726,140 | -48.0% | 331,571 | -15.7% | 0.02% | -48.5% |
TPST | Sell | TEMPEST THERAPEUTICS INC | $680,992 | -64.4% | 536,214 | -34.9% | 0.02% | -65.2% |
LPTX | Exit | LEAP THERAPEUTICS INC | $0 | – | -4,655,186 | -100.0% | -0.04% | – |
ETNB | Exit | 89BIO INCcall | $0 | – | -164,500 | -100.0% | -0.06% | – |
VERV | Exit | VERVE THERAPEUTICS INC | $0 | – | -558,837 | -100.0% | -0.19% | – |
AMYT | Exit | AMRYT PHARMA PLCsponsored ads | $0 | – | -1,325,625 | -100.0% | -0.46% | – |
RXDX | Exit | PROMETHEUS BIOSCIENCES INC | $0 | – | -1,031,550 | -100.0% | -2.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
INVITAE CORP | 35 | Q3 2023 | 1.8% |
BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
MACROGENICS INC | 35 | Q3 2023 | 0.5% |
COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
SC 13G | 2024-05-01 |
SC 13G/A | 2024-04-05 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.